Attached files
file | filename |
---|---|
8-K - FORM 8-K - IDENIX PHARMACEUTICALS INC | c15378e8vk.htm |
EX-10.1 - EXHIBIT 10.1 - IDENIX PHARMACEUTICALS INC | c15378exv10w1.htm |
EX-99.1 - EXHIBIT 99.1 - IDENIX PHARMACEUTICALS INC | c15378exv99w1.htm |
EX-1.1 - EXHIBIT 1.1 - IDENIX PHARMACEUTICALS INC | c15378exv1w1.htm |
Exhibit 5.1
April 8, 2011
Idenix Pharmaceuticals, Inc.
60 Hampshire Street
Cambridge, MA 02139
60 Hampshire Street
Cambridge, MA 02139
Re: Prospectus Supplement to Registration Statements on Form S-3
Ladies and Gentlemen:
This opinion is being furnished to you in connection with (i) the Registration Statement on Form
S-3 (File No. 333-153471) (the Initial Registration Statement) filed by Idenix Pharmaceuticals,
Inc., a Delaware corporation (the Company), with the Securities and Exchange Commission (the
Commission) for the purpose of registering with the Commission under the Securities Act of 1933,
as amended (the Securities Act), shares of the Companys common stock, $0.001 par value per share
(the Common Stock), which may be issued from time to time on a delayed or continuous basis
pursuant to Rule 415 under the Securities Act at an aggregate initial offering price not to exceed
$100,000,000 as set forth in the Registration Statement and the prospectus contained therein (the
Prospectus); and (ii) the Registration Statement on Form S-3 (File No. 333-173374) (the
Additional Registration Statement, and together with the Initial Registration Statement, the
Registration Statements) filed by the Company with the Commission under Rule 462(b) of the
Securities Act for the registration of shares of Common Stock which may be issued from time to time
at an initial offering price not to exceed an additional $9,826,883.55; and (iii) the prospectus
supplement, dated April 8, 2011 (the Prospectus Supplement), relating to the issue and sale
pursuant to the Registration Statements of up to 21,056,500 shares of Common Stock, including up to
2,746,500 shares of Common Stock issuable upon exercise of an over-allotment option granted by the
Company (the Shares).
The Shares are to be issued and sold by the Company pursuant to the underwriting agreement, dated
as of April 8, 2011 (the Underwriting Agreement), between the Company and J.P. Morgan Securities
LLC, the form of which will be filed with the Commission as Exhibit 1.1 to the Companys Current
Report on Form 8-K.
We are acting as counsel for the Company in connection with the issue and sale by the Company of
the Shares. We have examined signed copies of the Registration Statements and a copy of the
Prospectus Supplement, each as filed with the Commission. We have also examined and relied upon
the Underwriting Agreement, minutes of meetings of the stockholders and the Board of Directors of
the Company as provided to us by the Company, including committees thereof, of the Company as
provided to us by the Company, the Certificate of Incorporation and By-Laws of the Company, each as
restated and/or amended to date, and such other documents as we have deemed necessary for purposes
of rendering the opinion hereinafter set forth.
In our examination of the foregoing documents, we have assumed the genuineness of all signatures,
the authenticity of all documents submitted to us as originals, the conformity to original
documents of all
documents submitted to us as copies, the authenticity of the originals of such latter documents and
the legal competence of all signatories to such documents.
Idenix Pharmaceuticals, Inc.
April 8, 2011
Page 2
April 8, 2011
Page 2
We express no opinion herein as to the laws of any state or jurisdiction other than the state laws
of the State of New York, the General Corporation Law of the State of Delaware and the federal laws
of the United States of America.
Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly
authorized for issuance and, when issued and paid for in accordance with the terms and conditions
of the Underwriting Agreement, the Shares will be validly issued, fully paid and non-assessable.
It is understood that this opinion is to be used only in connection with the offer and sale of the
Shares while the Registration Statements are in effect and may not be used, quoted or relied upon
for any other purpose nor may this opinion be furnished to, quoted to or relied upon by any other
person or entity, for any purpose, without our prior written consent.
Please note that we are opining only as to the matters expressly set forth herein, and no opinion
should be inferred as to any other matters. This opinion is based upon currently existing
statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you
of any change in any of these sources of law or subsequent legal or factual developments which
might affect any matters or opinions set forth herein.
We hereby consent to the filing of this opinion in accordance with the requirements of Item
601(b)(5) of Regulation S-K under the Securities Act with the Commission as an exhibit to the
Current Report on Form 8-K to be filed by the Company in connection with the issue and sale of the
Shares and to the use of our name in the Prospectus Supplement under the caption Legal Matters.
In giving such consent, we do not hereby admit that we are in the category of persons whose consent
is required under Section 7 of the Securities Act or the rules and regulations of the Commission.
Very truly yours,
WILMER CUTLER PICKERING
HALE AND DORR LLP
WILMER CUTLER PICKERING
HALE AND DORR LLP
By: | /s/ Stuart R. Nayman | |||
Stuart R. Nayman, a Partner |